Citations

Clear

479 citation(s) found for "Tobias, JS".

Patient Selection and Outcomes for Bronchoscopic Lung Volume Reduction: A Single Center Experience
Martin, M., Scrodin, M. Dulohery, Edell, E.S., Peikert, T., Edell, Eric S. , Peikert, Tobias

Mayo Clinic

C40. INVESTIGATIONS IN INTERVENTIONAL PULMONOLOGY AND PLEURAL DISEASE | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A4096-A4096

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a4096 Get It

143 User Characteristics of Unique Men's Health Website
Alom, Mulham , Collins, S, Nelson, K. , Carlson, Stephanie K., Tentis, E, Ziegelmann, M., Trost, L, Köhler, Tobias , Nelson, K, Helo, Sevann , Trost, L

Mayo Clinic

The Journal of Sexual Medicine | April 26, 2022 | Volume: 19 | Issue: Supplement_1 | Pages: S74-S75

10.1016/j.jsxm.2022.01.407 Get It

ABSTRACT Introduction Covid-19 has helped drive all forms of medicine away from traditional brick and mortar medical interactions. Given the availability of online services to obtain treatments for ED, we developed a website to facilitate patient education, triage and men's health appointment scheduling. Objective We sought to assess characteristics of men who utilized a novel website to treat their ED. Methods We report on 50 patients who ultimately booked and attended appointments (video or in person) for erectile dysfunction. Patients found our website through our institution's main informational ED pages or through youtube links from our men's health video playlist library. Patients create an institutional account and are then asked a series of MD created questions designed to streamline patient triage and complete the majority of chart documentation ahead of the appointment. Patients are then sent videos relevant to their condition and future appointment options. Results 2300 users investigated the ED portion of the website with 1.8% of patients ultimately following through with an appointment. 13% of patients who explored the ED portion of the site created a user account that allows a questionnaire to be taken. 90% of men who began the ED questionnaire completed with a mean time of 11 minutes. 52% of men offered an appointment based on their responses completed the patient scheduling form. 71% of traffic was on mobile devices with 29% on desktop/tablet. Site use by time of day is shown in figure 1. Mean age of patients was 53. 92% of patients had ED that occurred > 6 months. Mean SHIM score was 8.2 (IQR 4-12). 80% of participants had both desire and opportunity for sexual activity, 20% did not meet both criteria and thus SHIM scores were less valid for these men. Of the users 28% had never tried pde5s, 32% had partial success with pde5s, 24% could not tolerate or afford pde5s and 42% had unsatisfactory results with pde5s. PDE5 naïve patients were seen by an internal medicine MD specializing in men's health, 10 were seen by surgeons as they requested IPPs and the rest were seen by a combination of men's health APPS and urology attendings for second line treatments and penile doppler. Interestingly, 66% of men were interested in undergoing penile doppler to better understand the etiology of their ED. Hypertension (40%) and diabetes (22%) were the most common medical comorbidities. 36% of the cohort had a strong family history of cardiac disease. Conclusions Men with ED can be effectively triaged through a website application. Most men with pde5 refractory ED wish to pursue penile doppler. The majority of patients seen had watched educational video material ahead of time, facilitating a more sophisticated and streamlined patient interaction. Disclosure No
217 Health Care Provider Knowledge and Attitudes about Erectile Dysfunction and Penile Implants
Roshandel, MR, Ziegelmann, M J, Helo, S, Köhler, TS, Collins, CS, Ziegelmann, M, Helo, S, Köhler, Tobias

Mayo Clinic

The Journal of Sexual Medicine | April 26, 2022 | Volume: 19 | Issue: Supplement_1 | Pages: S109-S110

10.1016/j.jsxm.2022.01.231 Get It

ABSTRACT Introduction Erectile dysfunction (ED) stems from a variety of etiologies and often requires a multidisciplinary approach to optimize patient care. Objective We sought to assess attitudes and confidence regarding the treatment of erectile dysfunction across different provider types. Methods Anonymous, email-based survey of physicians and advanced practice providers in the disciplines of urology, internal medicine, and family medicine. Responses were recorded using a five-point Likert scale. Descriptive statistical analysis of survey response data was performed. Results With 76 providers on this ongoing survey including 31 internists, 24 family physicians, and 21 urologists, 88% of providers believed there to be good options for erectile dysfunction after failing pills. Figure 1 shows attitudes of the modalities of “good” options and confidence in the ability to counsel about these options. Regarding if most patients report willingness to consider surgical intervention for ED when counseled about it an equal portion of providers had positive, neutral, and negative feedback. Figure 2 lists other specific attitudes and opinions about penile prosthesis (IPP) implants. Moreover, 78% emphasized the necessity of a multidisciplinary team-based approach to ED patients. However, only 30% of the participants were in agreement with referrals to specialists in sexual health including urologists. Conclusions This survey indicates a knowledge gap and low comfort level in 2nd and 3rd line ED treatments. Focused education on penile implant outcomes appears particularly helpful. Disclosure No
202 Impact of COVID-19 Pandemic in Online Interest in Erectile Dysfunction
Bearrick, Elizabeth , Ziegelmann, M., Köhler, Tobias , Helo, Sevann

Mayo Clinic

The Journal of Sexual Medicine | April 26, 2022 | Volume: 19 | Issue: Supplement_1 | Pages: S102-S103

10.1016/j.jsxm.2022.01.217 Get It

ABSTRACT Introduction The COVID-19 pandemic has had a significant impact on global health. During uncertain times, priorities amongst patients shifted as many faced health concerns, economic uncertainty, and isolation. Access to general medical care during 2020 was challenging for many Americans who spent the year in quarantine. Without access to care, we hypothesize that patients were less likely to search for treatment options for a non-emergent condition like erectile dysfunction. Objective Herein, we aim to report on Google search trends observed in the pre COVID and post COVID era. Methods Google Trends was analyzed using search terms related to erectile dysfunction between June 2018 and June 2021. The search volume index (SVI), a relative measure of search volume on Google, was obtained for the following terms: erectile dysfunction, viagra, trimix, penile pump, and penile implant. Student t test was used to compare changes in mean SVI for each month compared to the same month one year prior. Results Compared to one year prior, the search for erectile dysfunction remained relatively stable over time with the exception of three months (9% decline Mar 2020, 38% increase Jan 2021, 8% increase Jun 2021). When compared to the preceding year, searches for Viagra declined during 9/37 (24%) months analyzed including Mar-Jun 2020, which coincided with the early part of the COVID-19 pandemic (p<0.05 for all). The only statistically significant increase occurred Oct 2020, a 16% change compared to Oct 2019 (p<0.05). In contrast, search for trimix did not change significantly over time except for an increase of 62% Mar 2021 and 60% Apr 2021 (p<0.05 for all). Search for the term penile pump did not change over time except for a 16 and 10% decline early during the pandemic, Feb and Mar 2020, respectively (p<0.05 for all). Lastly, search for penile implant declined 37% Mar 2020 and 32% Apr 2020 compared to 2019, and increased by 67% May 2021 compared to May 2020 (p<0.05 for all). Conclusions COVID-19 represented a major global health crisis, raising concerns and uncertainties for many. Erectile dysfunction remained a constant source of online interest. Despite limited access to medical care for elective conditions, only a few isolated increases in Google SVI were noted, most of which occurred during 2021 compared to 2020. This may be a reflection of the general public's lack of familiarity with treatments other than phosphodiesterase-5 inhibitors. Disclosure No
62 Changes in Point of Maximal Curvature During Collagenase Clostridium Histolyticum Injections for Peyronie's Disease
Price, Trevor, Burgon, H, Green, B, Brearton, K, Savage, J, Ziegelmann, M., Köhler, Tobias , Trost, L, Helo, Sevann

Mayo Clinic

The Journal of Sexual Medicine | April 26, 2022 | Volume: 19 | Issue: Supplement_1 | Pages: S32-S33

10.1016/j.jsxm.2022.01.074 Get It

ABSTRACT Introduction Collagenase Clostridium Histolyticum (CCH) is commonly injected at the point of maximal curvature (POMC) for Peyronie's Disease (PD). However, many providers only evaluate the POMC at baseline and do not reassess during CCH injections. As PD plaques often extend over an extended region, it is currently unknown how much the POMC may change throughout a course of CCH treatment. Objective We sought to evaluate for changes in POMC between series among men undergoing CCH injections. Methods A prospective database has been maintained of PD men undergoing CCH injections at two institutions. POMC assessments were obtained prior to each series of injections after pharmacologic erection and were measured from the coronal margin to POMC. An analysis was performed comparing changes in POMC throughout the CCH course, including associated baseline demographic and disease characteristics. Results A total of 445 men (mean age 55.9, mean PD duration 30.6 months) underwent CCH injections from Jan 2014 through Feb 2021. The mean baseline composite curvature was 63.7° (SD 23.7), and the mean distance to curvature was 3.1 cm. Among men who completed 4 series of CCH injections, the mean improvement was 21° (SD 20.6) or 31.7% (SD 33%). In reviewing changes in POMC, the largest change observed at any point within the CCH series was a median 1 cm (IQR 0.5, 2 cm; range 0, 9.5 cm). Compared to baseline, 58% of men experienced a POMC change of 1 cm or greater, 25% 2 cm or greater, and 12% 3 cm or greater during the course of CCH treatment. Age, duration of PD, and baseline curvature were not associated with changes in POMC, although the POMC itself was associated with extent of changes, with proximal curves more likely to experience more notable changes compared to distal ones (p<0.0001). The total improvement in curve was also variably associated with change in POMC, with those experiencing greater improvements noted to have larger change in POMC (p<0.05 for changes in composite curvature and p=0.07 for percent change from baseline). These findings would suggest significant evolution of the POMC during a course of CCH, particularly among men with mid shaft or proximal curves and among those with greater curve improvements. Findings would support a role for repeat curvature assessments prior to each series of CCH injections. Conclusions Based on data from a prospective, two-institution series of PD men undergoing CCH injections, the POMC changes by ≥1 cm in the majority of men. Given the small volume injected with each CCH series, the clinical relevance of these findings and their impact on injector protocols merit further investigation. Disclosure No
HUS1 as a Potential Therapeutic Target in Urothelial Cancer
Lindner, Andrea Katharina , Furlan, Tobias, Orme, Jacob J. , Tulchiner, Gennadi , Staudacher, Nina, D’Andrea, David , Pichler, Renate , Pichler, Renate , Orme, Jacob J , D'Andrea, David , Čulig, Zoran

Mayo Clinic

Journal of Clinical Medicine | April 18, 2022 | Volume: 11 | Issue: 8 | Pages: 2208

10.3390/jcm11082208 | PMID 35456300 Get It

Platinum-based chemotherapy is the standard of care with concern to first-line systemic therapy for metastatic disease in urothelial cancer (UC). Resistance to chemotherapy despite an initial response is linked with the ability to remove platinum-based DNA adducts and to repair chemotherapy-induced DNA lesions by various DNA repair proteins. The Rad9-Rad1-HUS1 complex that is loaded onto DNA at sites of damage is involved in checkpoint activation as well as DNA repair. Here, we addressed for the first time the potential influence of HUS1 expression in urothelial carcinogenesis (using two human basal urothelial cancer cell lines UM-UC-3 and HT1197) and its role as a potential therapeutic target for predicting responses to platinum-based chemotherapy. Specific inhibition of HUS1 expression in both cell lines was achieved by specific siRNA and validated by Western blot. In order to define the possible importance of HUS1 in the regulation of cellular proliferation, parental and resistant cells were treated with increasing concentrations of either control or HUS1 siRNA. HUS1 protein expression was observed in both human basal urothelial cancer cell lines UM-UC-3 and HT1197. In cisplatin-sensitive cells, knock-down of HUS1 inhibited cellular proliferation in the presence of cisplatin. On the contrary, knock-down of HUS1 in resistant cells did not result in a re-sensitization to cisplatin. Finally, RNAseq data from the Cancer Genome Atlas provided evidence that HUS1 expression is a significant prognostic factor for poor survival in UC patients. In summary, HUS1 may acts as an oncogene in UC and might be a key determinant of the cellular response to cisplatin-based chemotherapy.
Botox for Erectile Dysfunction
Habashy, Engy, Köhler, Tobias S.

Mayo Clinic

The Journal of Sexual Medicine | April 9, 2022 | Volume: 19 | Issue: 7 | Pages: 1061-1063

10.1016/j.jsxm.2022.03.216 | PMID 35414489 Get It

Inequities in Therapy for Infantile Spasms: A Call to Action
Baumer, Fiona M. , Mytinger, John R. , Neville, Kerri, Abath, Christina Briscoe , Gutierrez, Camilo , Numis, Adam L. , Harini, Chellamani , He, Zihuai , Berg, Anne T. , Chu, Catherine J. , Gaillard, William D. , Pasupuleti, Archana, Samanta, Debopam , Singh, Rani K. , Singhal, Nilika S. , Wusthoff, Courtney J. , Yozawitz, Elissa , Shellhaas, Renée A. , Berg, Anne T , Chu, Catherine J , Baumer, Fiona M , Shellhaas, Renée A , Gaillard, William D , Yozawitz, Elissa G , Abath, Christina Briscoe , Wusthoff, Courtney J , Hussain, Shaun A. , Loddenkemper, Tobias , Wirrell, Elaine , Knupp, Kelly G. , Grinspan, Zachary M.

Mayo Clinic

Annals of Neurology | April 7, 2022 | Volume: 92 | Issue: 1 | Pages: 32-44

10.1002/ana.26363 | PMID 35388521 Get It

ObjectiveThe aim of this study was to determine whether selection of treatment for children with infantile spasms (IS) varies by race/ethnicity.MethodsThe prospective US National Infantile Spasms Consortium database includes children with IS treated from 2012 to 2018. We examined the relationship between race/ethnicity and receipt of standard IS therapy (prednisolone, adrenocorticotropic hormone, vigabatrin), adjusting for demographic and clinical variables using logistic regression. Our primary outcome was treatment course, which considered therapy prescribed for the first and, when needed, the second IS treatment together.ResultsOf 555 children, 324 (58%) were non‐Hispanic white, 55 (10%) non‐Hispanic Black, 24 (4%) non‐Hispanic Asian, 80 (14%) Hispanic, and 72 (13%) other/unknown. Most (398, 72%) received a standard treatment course. Insurance type, geographic location, history of prematurity, prior seizures, developmental delay or regression, abnormal head circumference, hypsarrhythmia, and IS etiologies were associated with standard therapy. In adjusted models, non‐Hispanic Black children had lower odds of receiving a standard treatment course compared with non‐Hispanic white children (odds ratio [OR], 0.42; 95% confidence interval [CI], 0.20–0.89; p = 0.02). Adjusted models also showed that children with public (vs. private) insurance had lower odds of receiving standard therapy for treatment 1 (OR, 0.42; CI, 0.21–0.84; p = 0.01).InterpretationNon‐Hispanic Black children were more often treated with non‐standard IS therapies than non‐Hispanic white children. Likewise, children with public (vs. private) insurance were less likely to receive standard therapies. Investigating drivers of inequities, and understanding the impact of racism on treatment decisions, are critical next steps to improve care for patients with IS. ANN NEUROL 2022;92:32–44
Quality of Life and its Determinants in Patients With Adrenal Insufficiency: A Survey Study at 3 Centers in the United States
Li, Dingfeng , Hamidi, Oksana , Westfall, Ashleigh A, Suresh, Malavika, Else, Tobias , Vaidya, Anand , Hamidi, Oksana , Else, Tobias , Bancos, Irina , Brand, Sarah, Westfall, Ashleigh, Bancos, Irina

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 29, 2022 | Volume: 107 | Issue: 7 | Pages: e2851-e2861

10.1210/clinem/dgac175 | PMID 35350067 Get It

Abstract Context Current evidence on determinants of quality of life (QoL) in patients with adrenal insufficiency (AI) is limited. Objective This work aimed to identify the determinants of QoL in different subtypes of AI. Methods This multicenter cross-sectional survey study was conducted using a patient-centered questionnaire, the Short Form-36. Results Of 529 participants, 223 (42.2%) had primary AI, 190 (35.9%) had secondary AI, and 116 (21.9%) had glucocorticoid-induced AI. Median age was 58 years (interquartile range: 43-68 years) and 342 (64.8%) were women. In multivariable analyses, patients were more likely to report worse physical scores if they were women (odds ratio [OR]: 3.3; 95% CI, 1.8-6.0), had secondary AI or glucocorticoid-induced AI (OR: 2.5; 95% CI, 1.4-4.3), had shorter duration of AI (OR: 2.0; 95% CI, 1.1-3.6), were treated with more than 25 mg hydrocortisone equivalent daily (OR: 2.3; 95% CI, 1.2-4.6), had more comorbidities related to glucocorticoid excess (OR: 2.3; 95% CI, 1.3-4.0), reported a higher financial burden from AI (OR: 2.1; 95% CI, 1.3-3.6), and reported difficulties with AI management (OR: 2.5; 95% CI, 1.2-5.2). Women (OR: 2.1; 95% CI, 1.08-4.0), shorter duration of AI (OR: 2.4; 95% CI, 1.4-4.3), higher financial burden (OR: 2.3; 95% CI, 1.3-4.0), difficulties with AI management (OR: 2.6; 95% CI, 1.4-4.9), and lack of family support (OR: 9.1; 95% CI, 2.3-33.3) were associated with worse mental component scores. Conclusion In patients with AI, QoL could be improved by addressing certain determinants, such as avoiding GC overreplacement, providing in-depth education on self-management, offering more comprehensive insurance coverage, and ensuring better family support.
Using advanced racial and ethnic identity demographics to improve surveillance of work‐related conditions in an occupational clinic setting
Montoya‐Barthelemy, Andre , Leniek, Karyn , Bannister, Emily L., Rushing, Marcus D. , Abrar, Fozia A., Baumann, Tobias E., Manly, Madeleine, Wilhelm, Jonathan , Niece, Ashley D., Riester, Scott M. , Sellman, Jonathan, Anderson, Paul J., Bovard, Ralph , Pronk, Nicolas P., McKinney, Zeke J. , Montoya-Barthelemy, Andre G , Riester, Scott , Kim, Hyun , McKinney, Zeke J , Wilhelm, Jonathan, Desai, Jay

Mayo Clinic

American Journal of Industrial Medicine | March 2, 2022 | Volume: 65 | Issue: 5 | Pages: 357-370

10.1002/ajim.23332 | PMID 35235683 Get It

AbstractBackgroundAlthough racial and ethnic identities are associated with a multitude of disparate medical outcomes, surveillance of these subpopulations in the occupational clinic setting could benefit enormously from a more detailed and nuanced recognition of racial and ethnic identity.MethodsThe research group designed a brief questionnaire to capture several dimensions of this identity and collected data from patients seen for work‐related conditions in four occupational medicine clinics from May 2019 through March 2020. Responses were used to calculate the sensitivity and specificity of extant racial/ethnic identity data within our electronic health records system, and were compared to participants' self‐reported industry and occupation, coded according to North American Industry Classification System and Standard Occupational Classification System listings.ResultsOur questionnaire permitted collection of data that defined our patients' specific racial/ethnic identity with far greater detail, identified patients with multiple ethnic identities, and elicited their preferred language. Response rate was excellent (94.2%, n = 773). Non‐White participants frequently selected a racial/ethnic subcategory (78.1%–92.2%). Using our race/ethnicity data as a referent, the electronic health record (EHR) had a high specificity (>87.1%), widely variable sensitivity (11.8%–82.2%), and poorer response rates (75.1% for race, 82.5% for ethnicity, as compared to 93.8% with our questionnaire). Additional analyses revealed some industries and occupations disproportionately populated by patients of particular racial/ethnic identities.ConclusionsOur project demonstrates the usefulness of a questionnaire which more effectively identifies racial/ethnic subpopulations in an occupational medicine clinic, permitting far more detailed characterization of their occupations, industries, and diagnoses.